Evidence map›Paper›PMID 39004727›Full record

ArticleJournal of biomedical science2024

Unraveling the differential mechanisms of revascularization promoted by MSCs & ECFCs from adipose tissue or umbilical cord in a murine model of critical limb-threatening ischemia.

Marta Rojas-Torres, Lucía Beltrán-Camacho, Ana Martínez-Val, Ismael Sánchez-Gomar, Sara Eslava-Alcón, Antonio Rosal-Vela, Margarita Jiménez-Palomares, Esther Doiz-Artázcoz, Mario Martínez-Torija, Rafael Moreno-Luna and 2 more

Abstract read
In one paragraph

Article in Journal of biomedical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta Rojas-TorresBiomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain.
Lucía Beltrán-CamachoCell Biology, Physiology and Immunology Department, University of Cordoba, Cordoba, 14004, Spain.
Ana Martínez-ValNational Center of Cardiovascular Research Carlos III (CNIC), Madrid, 28029, Spain.
Ismael Sánchez-GomarBiomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain.
Sara Eslava-AlcónBiomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain.
Antonio Rosal-VelaBiomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain.
Margarita Jiménez-PalomaresBiomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain.
Esther Doiz-ArtázcozAngiology & Vascular Surgery Unit, Hospital Universitario Puerta del Mar, Cadiz, Spain.
Mario Martínez-TorijaPathophysiology and Regenerative Medicine Group, Hospital Nacional de Parapléjicos (SESCAM), Toledo, 45071, Spain.
Rafael Moreno-LunaPathophysiology and Regenerative Medicine Group, Hospital Nacional de Parapléjicos (SESCAM), Toledo, 45071, Spain. rmluna@sescam.jccm.es.
Jesper V OlsenNovo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.
Ma Carmen Duran-RuizBiomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain. maricarmen.duran@gm.uca.es.ORCID http://orcid.org/0000-0003-3954-3734

Funding

Consejería de Salud y Consumo, Junta de Andalucía PI0026-2017Consejería de Salud y Consumo, Junta de Andalucía PI20-00932HORIZON EUROPE European Innovation Council EPICS-XS-823839Instituto de Salud Carlos III PI20-00716Instituto de Salud Carlos III PI20-00784Ministerio de Ciencia, Innovación y Universidades PID2022-137080OB-I00Novo Nordisk Foundation Center for Protein Research, University of Copenhagen NNF14CC0001
6 · The paper itself

Abstract

backgroundCritical limb-threatening ischemia (CLTI) constitutes the most severe manifestation of peripheral artery disease, usually induced by atherosclerosis. CLTI patients suffer from high risk of amputation of the lower extremities and elevated mortality rates, while they have low options for surgical revascularization due to associated comorbidities. Alternatively, cell-based therapeutic strategies represent an effective and safe approach to promote revascularization. However, the variability seen in several factors such as cell combinations or doses applied, have limited their success in clinical trials, being necessary to reach a consensus regarding the optimal "cellular-cocktail" prior further application into the clinic. To achieve so, it is essential to understand the mechanisms by which these cells exert their regenerative properties. Herein, we have evaluated, for the first time, the regenerative and vasculogenic potential of a combination of endothelial colony forming cells (ECFCs) and mesenchymal stem cells (MSCs) isolated from adipose-tissue (AT), compared with ECFCs from umbilical cord blood (CB-ECFCs) and AT-MSCs, in a murine model of CLTI.

methodsBalb-c nude mice (n:32) were distributed in four different groups (n:8/group): control shams, and ischemic mice (after femoral ligation) that received 50 µl of physiological serum alone or a cellular combination of AT-MSCs with either CB-ECFCs or AT-ECFCs. Follow-up of blood flow reperfusion and ischemic symptoms was carried out for 21 days, when mice were sacrificed to evaluate vascular density formation. Moreover, the long-term molecular changes in response to CLTI and both cell combinations were analyzed in a proteomic quantitative approach.

resultsAT-MSCs with either AT- or CB-ECFCs, promoted a significant recovery of blood flow in CLTI mice 21 days post-ischemia. Besides, they modulated the inflammatory and necrotic related processes, although the CB group presented the slowest ischemic progression along the assay. Moreover, many proteins involved in the repairing mechanisms promoted by cell treatments were identified.

conclusionsThe combination of AT-MSCs with AT-ECFCs or with CB-ECFCs promoted similar revascularization in CLTI mice, by restoring blood flow levels, together with the modulation of the inflammatory and necrotic processes, and reduction of muscle damage. The protein changes identified are representative of the molecular mechanisms involved in ECFCs and MSCs-induced revascularization (immune response, vascular repair, muscle regeneration, etc.).

Indexed as

Adipose TissueDisease Models, AnimalIschemiaMesenchymal Stem CellsMice, Inbred BALB CMice, NudeAnimalsEndothelial CellsHumansMaleMesenchymal Stem Cell TransplantationMiceNeovascularization, PhysiologicUmbilical CordAdipose tissueCell therapyCritical limb-threatening ischemiaECFCsMSCsProteomics

Identifiers

PMID39004727
PMCPMC11247736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.